Jim Simons Compass Pathways PLC Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Compass Pathways PLC stock. As of the latest transaction made, Renaissance Technologies LLC holds 263,800 shares of CMPS stock, worth $2.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

263,800

Previous 16,300 1518.4%

Holding current value

$2.25 Million

Previous $136,000 1555.88%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	N/A	247,500 Added 1518.4%	263,800 $2.25 Million
Q1 2024 May 13, 2024	BUY	N/A	16,300 New	16,300 $136,000
Q1 2023 May 12, 2023	SELL	$7.32 - $10.85 $1.19 Million - $1.76 Million	-162,500 Reduced 88.85%	20,400 $203,000
Q4 2022 Feb 13, 2023	SELL	$7.84 - $11.68 $270,229 - $402,586	-34,468 Reduced 15.86%	182,900 $1.47 Million
Q3 2022 Nov 14, 2022	BUY	$10.73 - $20.07 $1.35 Million - $2.53 Million	126,068 Added 138.08%	217,368 $2.33 Million
Q2 2022 Aug 12, 2022	SELL	$6.76 - $14.18 $256,204 - $537,422	-37,900 Reduced 29.33%	91,300 $988,000
Q1 2022 May 13, 2022	BUY	$11.13 - $23.04 $754,280 - $1.56 Million	67,770 Added 110.32%	129,200 $1.67 Million
Q4 2021 Feb 11, 2022	BUY	$21.81 - $48.96 $500,103 - $1.12 Million	22,930 Added 59.56%	61,430 $1.36 Million
Q3 2021 Nov 12, 2021	SELL	$29.03 - $38.62 $2.04 Million - $2.72 Million	-70,400 Reduced 64.65%	38,500 $1.15 Million
Q2 2021 Aug 13, 2021	BUY	$32.29 - $39.68 $3.52 Million - $4.32 Million	108,900 New	108,900 $4.16 Million

Others Institutions Holding CMPS

# of Institutions

146

Shares Held

29.2M

Call Options Held

156K

Put Options Held

563K

View Full List

About COMPASS Pathways plc

Ticker CMPS
Exchange NASDAQ
Sector Healthcare
Industry Medical Care Facilities
Shares Outstandng 42,522,400
Market Cap $363M
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...

More about CMPS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account